Effect of Sildenafil on Coronary Slow Flow Phenomenon

Effect of Sildenafil on Ischemic Cardiac Clinical and paraclinical manifestations in patients with Coronary Slow Flow Phenomenon : a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220223054103N1

Enrollment

Registered

2022-04-28

Start date

2022-06-22

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Slow Flow Phenomenon. Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris

Interventions

Intervention 1: Intervention group: The use of Sildenafil starts with a daily dose of 50 mg orally and continues for 12 weeks. Intervention 2: Control group: The placebo is started once daily orally a

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with definitive diagnosis of CSFP on coronary angiography. Patients with clinical signs of ischemia including typical angina pectoris (at least 2-3 minutes retrosternal and compressive angina) or dyspnea (equivalent to angina).

Exclusion criteria

Exclusion criteria: Patients with myocardial infarction or PCI or CABG or valve replacement or valve repair Patients with Obstructive CAD (stenoses greater than 40%) Patients with hepatic or renal failure or CVA or COPD or Cancer or acute infectious disease such as Covid 19 Patients older than 75 years or less than 30 years Patients with low systolic blood pressure ( 180/100) Patients with LVEF <50%

Design outcomes

Primary

Measure	Time frame
Chest Pain according to Canadian cardiovascular society classification. Timepoint: Begining of the study, 1 , 2 , 3 months after taking sildenafil. Method of measurement: Canadian cardiovascular society classification questionnaire.;Duke treadmill score. Timepoint: Begining of the study, 3 months after taking sildenafil or placebo. Method of measurement: Scoring based on the Duke treadmill score.;Functional capacity in exercise treadmill test. Timepoint: Begining of the study, 3 months after taking sildenafil or placebo. Method of measurement: Achived METs.	—

Measure

Time frame

Chest Pain according to Canadian cardiovascular society classification. Timepoint: Begining of the study, 1 , 2 , 3 months after taking sildenafil. Method of measurement: Canadian cardiovascular society classification questionnaire.;Duke treadmill score. Timepoint: Begining of the study, 3 months after taking sildenafil or placebo. Method of measurement: Scoring based on the Duke treadmill score.;Functional capacity in exercise treadmill test. Timepoint: Begining of the study, 3 months after taking sildenafil or placebo. Method of measurement: Achived METs.

—

Secondary

Measure	Time frame
ETT changes. Timepoint: begining of the study and 3 months later. Method of measurement: exercise treadmill test.;Blood pressure. Timepoint: begining of the study and 1 and 2 and 3 months later. Method of measurement: Blood pressure monitor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Entezari

Yazd University of Medical Sciences

aminentezari.2013@gmail.com+98 35 3523 1420

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026